"
We have commenced the process of penetrating the Chinese market. To this end, we are:
| | ● | undergoing clinical trials in a few hospitals in Guangzhou for our Prizma products; |
|---|
| 1 | | ● | negotiating commercial agreements with Chinese companies to provide diagnostic services; |
|---|
| 2 | | ● | carrying out marketing activities in China, such as exhibiting at the China International Import Expo in Shanghai; and |
|---|
| 3 | | ● | starting CFDA approval process for the Extended Holter patch System. |
|---|
Implementation of Our Strategy in Europe and Asia Pacific
We have expanded our footprint to the United Kingdom, and began our operations at G Medical Innovations UK, Ltd. (G Medical UK). Located in South Hampton, G Medical UK will offer our cardiac monitoring service platform and Prizma solution to a wide range of healthcare providers, homecare agencies and other institutions throughout the country.
Driven by the need for accessible healthcare, the Asia Pacific market is expected to be an attractive growth market. Low penetration of medical practitioners and growing rural population in the Asia Pacific region are expected to open avenues for revenue generation.
We have relationships with Telcos and fulfilment houses throughout Europe and Asia. As various milestones are met and as business increases, we will aim to cultivate markets globally in an efficient and economically viable manner. The fulfilment houses that we are in discussions with are companies which are also entrenched in servicing logistics programs of major mass merchants in each country in which they are located"
